NEW YORK, NY / ACCESS Newswire / March 20, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Novo Nordisk (NVO) reachead $78.79 at the closing of the latest trading day, reflecting a -0.27% change compared to its last close.

Allurion Technologies' gastric balloon and Novo Nordisk's semaglutide achieved 20.3% weight loss in a trial. Read more here.

Eli Lilly (LLY) stock in focus as the company launches its weight loss therapy Mounjaro in India, beating its rival Novo Nordisk (NVO). Read more here.

Eli Lilly (LLY) launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk (NVO) for a ...

Investing.com -- U.S. pharmaceutical company Eli Lilly (NYSE: LLY) has introduced its diabetes and weight-loss drug Mounjaro ...

European equities traded in the US as American depositary receipts were tracking lower late Thursday morning, declining 0.47% to 1,438.05 on the S&P Europe Select ADR Index. From continental Europe, ...

GSK GSK stock has risen 16.9% year to date compared with an increase of 7.0% for the industry. The stock has also ...

The Association of the British Pharmaceutical Industry (ABPI) reinstated Novo Nordisk’s membership in the group. 1 The ...

BlackRock, Novo Nordisk A/S, Apollo Global Management, Black Diamond Therapeutics, and Blackstone are the five Growth stocks ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has ...

Eli Lilly says it is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both GIP and ...